| 1.12 -0.01 (-0.88%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.74  |
1-year : | 2.02 |
| Resists | First : | 1.49 |
Second : | 1.73 |
| Pivot price | 1.21 |
|||
| Supports | First : | 1.11 |
Second : | 0.92 |
| MAs | MA(5) : | 1.15 |
MA(20) : | 1.24 |
| MA(100) : | 1.5 |
MA(250) : | 1.39 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 11.5 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GERN ] has closed above bottom band by 4.1%. Bollinger Bands are 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.18 | 1.18 - 1.19 |
| Low: | 1.09 - 1.1 | 1.1 - 1.11 |
| Close: | 1.11 - 1.12 | 1.12 - 1.13 |
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Tue, 09 Jun 2026
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch - AD HOC NEWS
Mon, 08 Jun 2026
GERN: RYTELO’s expanding use and strong clinical data drive steady growth and future pipeline potential - TradingView
Mon, 08 Jun 2026
GERN: RYTELO’s uptake accelerates as education, guidelines, and real-world data drive broader adoption - TradingView
Fri, 05 Jun 2026
GERN Stock Chart | GERON CORP (NASDAQ:GERN) - ChartMill
Thu, 04 Jun 2026
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN) - Yahoo Finance Singapore
Thu, 04 Jun 2026
Geron Strengthens Board with Biopharma Veterans as RYTELO Gains Altitude - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 642 (M) |
| Shares Float | 536 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 79.2 (%) |
| Shares Short | 70,150 (K) |
| Shares Short P.Month | 82,160 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | -34.4 % |
| Operating Margin | -0.5 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 30.8 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -126 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -10.19 |
| PEG Ratio | 0 |
| Price to Book value | 3.11 |
| Price to Sales | 3.66 |
| Price to Cash Flow | -5.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|